Ghana’s $109m health deal rejection: what it means for patients, jobs and the economy

Accra has walked away from a US health package worth roughly $109 million, citing demands for medical records, pathogen information and what it calls humiliating limits on its own medicine rules. The consequences will be felt far beyond government offices — in clinics, pharmacies and households across the country.

The real-world fallout: patients, businesses and public finances

The decision, confirmed by President John Dramani Mahama at the Council on Foreign Relations in New York on 25 September, raises a pointed question: what price does a nation pay when it trades away control of its health data for foreign money?

For ordinary Ghanaians, the immediate effects are twofold. On one hand, rejecting the deal means roughly $109 million in US funding over five years will not flow into the system. On the other, accepting it could have exposed sensitive health records and pathogen profiles to outside access — a risk that officials say went well beyond what is normally required. The full programme was valued at about $300 million when complementary Ghanaian contributions are counted.

“Who takes the medical records of another country?” Mahama asked, summing up his government’s position.

What was actually on the table

The dispute does not hinge on the money itself. It centres on the conditions attached to it.

Arnold Kavaarpuo, executive director of Ghana’s Data Protection Commission and a participant in the negotiations, has said some provisions would have allowed access to sensitive health data in circumstances where individuals could potentially be identified. The scope of that access, he argued, exceeded what is usually necessary.

According to reporting by the BMJ, the draft would have opened health data and pathogen samples to 16 US companies. Many clauses in the new US health agreements remain hard to scrutinise publicly because not all negotiated texts have been released. That incomplete picture makes it difficult to say definitively that Washington demanded unrestricted access to all Ghanaian medical records. What is documented, however, is Ghana’s concern about the breadth of access to health and pathogen data.

Why this data carries so much weight

Health records are not just paperwork. They reveal which diseases are circulating, where they are spreading, which populations are most exposed and how outbreaks evolve.

Pathogen data can also be enormously valuable for science, feeding research into vaccines, treatments and surveillance of new epidemics.

That is why other African governments are watching closely. In February 2026, Jean Kaseya, director-general of the Africa Centres for Disease Control and Prevention (Africa CDC), raised serious concerns about data- and pathogen-sharing provisions in the new US health agreements. Some deals, it was reported, required rapid sharing of sensitive data without guaranteeing African countries access to any treatments or vaccines developed from it.

Ghana, in other words, is not an isolated case.

An economic calculation, not just a health one

The rejection also lands in a difficult financial context.

After much US aid was suspended, Ghana has been trying to reduce its reliance on external funding. In February 2025, the presidency estimated the shortfall from the suspension of USAID financing at $156 million, of which $78.2 million directly affected essential health programmes.

The Mahama government now champions what it calls “health sovereignty.” That direction was reinforced in September with the launch of the A Sovereign Future for Health report, presented under the Accra Reset initiative. The document proposes cutting Southern countries’ dependence on foreign funding and strengthening their own health systems.

Accra’s message is clear: Ghana wants to keep working with foreign partners, but on terms it considers more balanced.

The medicines flashpoint

Another friction point is particularly sensitive for businesses and consumers alike.

According to Mahama, the draft would have exempted certain medicines and medical products supplied under the programme from oversight by Ghana’s Food and Drugs Authority (FDA).

The US government has not publicly confirmed that detail. Asked about it, a State Department spokesperson said Washington does not discuss the specifics of bilateral negotiations, while adding that the US continues to look for ways to strengthen its partnership with Ghana.

Still, if the provision was indeed in the text shown to Ghanaian officials, it helps explain Accra’s firmness: for the authorities, health financing should not shrink the national regulator’s ability to vet medical products used on its territory.

What the US side says

Washington has not detailed the contested clauses publicly.

A State Department spokesperson said the US does not disclose the details of bilateral negotiations, while maintaining that Washington is still seeking ways to deepen its partnership with Ghana.

Because the full text has not been released, several essential questions cannot be answered: exactly what data would have been accessible, to which US companies or institutions, under what circumstances individuals could have been identified, how long data would have been retained, and what legal safeguards would have protected Ghanaian patients.

On these points, public information remains incomplete.

A debate that reaches well past Ghana’s borders

That may be the deeper significance of the affair.

For decades, many African health systems have relied on funding, medicines, equipment and programmes from abroad. Those partnerships have saved lives and helped fight major diseases.

But the digital transformation of health is changing the nature of cooperation. Aid is no longer only about money, medicines or equipment. It can also grant access to a strategic resource: data.

And Ghana has just signalled that it intends to keep control of that resource.

Mahama says his government rejected the draft after review by the Ministry of Health and deliberation by Cabinet. He says the decision had the backing of the entire government and was taken very quickly.

Ghana will now have to show it can fill the funding gap without undermining its health programmes.

But for Accra, the choice appears deliberate: better to look for other partners than to sign an agreement the government considers incompatible with health sovereignty and the protection of Ghanaians’ data.

The question Ghana is now putting to its foreign partners is simple: when Africa receives aid to treat its people, must it also surrender control of information about those people?

The debate has probably only just begun.

By Daniel Mbami — Politics and Security